After Doc Uproar, NCCN Reverses Prostate Cancer Guidance After Doc Uproar, NCCN Reverses Prostate Cancer Guidance

The cancer organization today largely reinstated its former advice that men with low-risk prostate cancer be offered active surveillance as the lone'preferred'initial treatment option.News Alerts
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Related Links:

Conditions:   Prostate Cancer;   Survivorship;   Physical Function;   Physical Activity;   Old Age Intervention:   Sponsors:   Sykehuset Innlandet HF;   Norwegian University of Science and Technology Recruiting
Source: - Category: Research Source Type: clinical trials
Prostate cancer (PC) is a 2nd leading cause of cancer death in the USA among men. We aim to investigate incidence, characteristics, and risk factors for PC in patients diagnosed with Inflammatory bowel disease (IBD) using Cerner Health Facts, a national longitudinal database representing approximately 69 million patients.
Source: Gastroenterology - Category: Gastroenterology Authors: Tags: Diagnostics in IBD Source Type: research
Cancer Res. 2022 Jan 19:canres.2609.2021. doi: 10.1158/0008-5472.CAN-21-2609. Online ahead of print.ABSTRACTCancer therapy often results in heterogeneous responses in different metastatic lesions in the same patient. Inter- and intra-tumor heterogeneity in signaling within various tumor compartments and its impact on therapy are not well characterized due to the limited sensitivity of single cell proteomic approaches. To overcome this barrier, we applied single cell mass cytometry with a customized 26-antibody panel to PTEN-deleted orthotopic prostate cancer xenograft models to measure the evolution of kinase activities in...
Source: Cell Research - Category: Cytology Authors: Source Type: research
Measurements of the urethra seen on MRI exams prior to surgery may predict urinar...Read more on AuntMinnie.comRelated Reading: When to biopsy: How prostate MRI can transform best practice PET/MRI bests MRI alone for detecting recurrent prostate cancer ASTRO: Is hormone therapy after prostate surgery needed? Guidelines revised for rad therapy after prostatectomy
Source: Headlines - Category: Radiology Source Type: news
PurposeGrowing evidence shows that circulating tumor cells (CTCs) become more aggressive after the epithelial–mesenchymal transition (EMT), though the clinical significance of CTCs undergoing EMT in oligometastatic hormone-sensitive prostate cancer (omHSPC) patients has not yet been reported. Accordingly, the aim of this study was to detect the CTC level and investigate the clinical significance of mesenchymal CTCs in omHSPC patients who underwent cytoreductive radical prostatectomy (CRP).Materials and MethodsBlood samples were drawn from 54 omHSPC patients who underwent CRP. The CanPatrol CTC enrichment technique wa...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsOur study suggests the performance of bpMRI- and mpMRI-based radiomics models show no significant difference, which indicates that omitting DCE imaging in radiomics can simplify the process of analysis. Adding radiomics to PI-RADS v2.1 may improve the performance to predict csPCa.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: The study showed that the level of knowledge of PCa is low. Thus, community and individuals should collaborate to increase awareness by having more awareness campaigns, disseminating the information through the media, and encouraging men to do screening tests as indicated. In addition, including more Saudi Arabia cities in future studies is preferable to have more precise outcomes.
Source: Urology Annals - Category: Urology & Nephrology Authors: Source Type: research
no Yuta Shibamoto We retrospectively evaluated the three-year patient-reported quality of life (QOL) after moderately hypofractionated proton therapy (MHPT) for localized prostate cancer in comparison with that after normofractionated PT (NFPT) using the Expanded Prostate Cancer Index Composite-50. Patients who received MHPT (60–63 Gy (relative biological effectiveness equivalents; RBE)/20–21 fractions) (n = 343) or NFPT (74–78 Gy (RBE)/37–39 fractions) (n = 296) between 2013 and 2016 were analyzed. The minimum clinically important difference (MCID) threshold was defined as one...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
iams Ian Vela Prostate cancer is the most commonly diagnosed solid-organ cancer amongst males worldwide. Metastatic castrate-resistant prostate cancer (mCRPC) is a rapidly fatal end-sequelae of prostate cancer. Therapeutic options for men with mCRPC are limited and are not curative in nature. The recent development of chimeric antigen receptor T-cell (CAR-T) therapy has revolutionised the treatment of treatment-resistant haematological malignancies, and several studies are underway investigating the utility of this technology in the treatment of solid tumours. In this review, we evaluate the current treatment options...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Oncogene, Published online: 20 January 2022; doi:10.1038/s41388-021-02155-zTargeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer
Source: Oncogene - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Hematology | Prostate Cancer